The Supreme Court last week ruled unanimously that human genes are a “product of nature” and therefore may not be patented. The ruling quashed patents held by pharmaceutical company Myriad Genetics on two genes linked to breast and ovarian cancer. Myriad argued they had “isolated” the genes by spending millions of dollars on research. Justice Clarence Thomas stated that “naturally occurring DNA” may not be treated in the same way as “human-made” inventions. Myriad had been the only company legally able to perform expensive tests for hereditary breast and ovarian cancers. Within hours of the ruling, several other companies announced plans to offer testing for the genes.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
5 exclusive cartoons about Trump and Putin negotiating peaceCartoons Artists take on alternative timelines, missing participants, and more
-
The AI arms raceTalking Point The fixation on AI-powered economic growth risks drowning out concerns around the technology which have yet to be resolved
-
Why Jannik Sinner's ban has divided the tennis worldIn the Spotlight The timing of the suspension handed down to the world's best male tennis player has been met with scepticism
